S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

Pharmacyte Biotech Stock Price, News & Analysis (OTCMKTS:PMCB)

$0.04
0.00 (0.00 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$0.04
Now: $0.04
$0.04
50-Day Range
$0.03
MA: $0.04
$0.04
52-Week Range
$0.03
Now: $0.04
$0.07
Volume1.65 million shs
Average Volume1.80 million shs
Market Capitalization$47.55 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PMCB
CUSIPN/A
Phone917-595-2850

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-4,070,000.00

Miscellaneous

Employees4
Outstanding Shares1,328,171,000
Market Cap$47.55 million
Next Earnings Date10/23/2019 (Estimated)
OptionableNot Optionable

Receive PMCB News and Ratings via Email

Sign-up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter.


Pharmacyte Biotech (OTCMKTS:PMCB) Frequently Asked Questions

What is Pharmacyte Biotech's stock symbol?

Pharmacyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB."

When is Pharmacyte Biotech's next earnings date?

Pharmacyte Biotech is scheduled to release their next quarterly earnings announcement on Wednesday, October 23rd 2019. View Earnings Estimates for Pharmacyte Biotech.

Has Pharmacyte Biotech been receiving favorable news coverage?

News stories about PMCB stock have been trending negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pharmacyte Biotech earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Pharmacyte Biotech.

Who are some of Pharmacyte Biotech's key competitors?

What other stocks do shareholders of Pharmacyte Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmacyte Biotech investors own include Cronos Group (CRON), OrganiGram (OGI), Green Thumb Industries (GTBIF), GW Pharmaceuticals PLC- (GWPH), Aurora Cannabis (ACB), Canopy Growth (CGC), Cannabis Science (CBIS), mCig (MCIG), Medical Marijuana (MJNA) and NVIDIA (NVDA).

Who are Pharmacyte Biotech's key executives?

Pharmacyte Biotech's management team includes the folowing people:
  • Mr. Kenneth L. Waggoner, Chairman, CEO, Pres, Gen. Counsel & Sec. (Age 71)
  • Mr. Carlos A. Trujillo, CFO & Director (Age 61)
  • Dr. Gerald W. Crabtree, COO & Director (Age 78)
  • Prof. Walter H. Günzburg, Chief Scientific Officer & Consultant (Age 60)
  • Dr. Mark L. Rabe, Director of Cannabis Program Devel. and Member of Medical & Scientific Advisory Board

How do I buy shares of Pharmacyte Biotech?

Shares of PMCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pharmacyte Biotech's stock price today?

One share of PMCB stock can currently be purchased for approximately $0.04.

How big of a company is Pharmacyte Biotech?

Pharmacyte Biotech has a market capitalization of $47.55 million. Pharmacyte Biotech employs 4 workers across the globe.View Additional Information About Pharmacyte Biotech.

What is Pharmacyte Biotech's official website?

The official website for Pharmacyte Biotech is http://www.pharmacytebiotech.com/.

How can I contact Pharmacyte Biotech?

Pharmacyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The company can be reached via phone at 917-595-2850 or via email at [email protected]


MarketBeat Community Rating for Pharmacyte Biotech (OTCMKTS PMCB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  190 (Thanks for Voting!)
Underperform Votes:  208 (Thanks for Voting!)
Total Votes:  398
MarketBeat's community ratings are surveys of what our community members think about Pharmacyte Biotech and other stocks. Vote "Outperform" if you believe PMCB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMCB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel